[Genetics and treatment of early infantile epileptic encephalopathies]
A A Sharkov1, I V Sharkova2, E D Belousova1
1Veltischev Research and Clincal Institute of Pediatrics in Pirogov Russian National Research Medical University, Moscow, Russia.
Insights
Epileptic encephalopathies (EE) are progressive neurological disorders often caused by genetic factors. Accurate genetic diagnosis is crucial for targeted treatments and better outcomes in affected children.
Area of Science:
- Neurology
- Genetics
- Pediatrics
Background:
- Epileptic encephalopathies (EE) are progressive conditions causing neurocognitive deficits and frequent seizures.
- EE accounts for 15% of childhood epilepsy and 40% of seizures in infants under three.
- Ten distinct EE syndrome forms are recognized.
Purpose of the Study:
- To review the genetic basis of early-onset epileptic encephalopathies.
- To discuss differentiated treatment approaches for specific EE syndromes.
- To highlight the importance of genetic diagnosis for targeted therapy.
Main Methods:
- Review of recent publications on genetic factors in EE.
- Analysis of genetic heterogeneity and inheritance patterns in early EE.
- Examination of targeted therapy effectiveness for monogenic EE forms.
Main Results:
- Genetic factors contribute to 70-80% of epilepsy cases, with 40% of idiopathic epilepsies being monogenic.
- Thirty-five EE-associated genes have been identified, showing significant genetic heterogeneity.
- Targeted therapies like stiripentol, diphenine, and levetiracetam show effectiveness in specific monogenic EE forms.
Conclusions:
- Accurate genetic diagnosis of early infantile EE is essential.
- This diagnosis aids in preventive strategies for at-risk families.
- Personalized genetic approaches improve treatment efficacy for EE.
Abstract:
Epileptic encephalopathies (EE) are the group of progressive conditions with various etiologies that can produce neurocognitive deficit both per se and due to constant epileptiform discharges. Epileptic encephalopathies constitute about 15% of epilepsy in childhood and 40% of all seizures occurring in the first 3 years of life. Ten syndrome forms of EE are identified. Genetic factors contribute to 70-80% of all epileptic diseases and approximately 40% of idiopathic epilepsies have a monogenic mode of inheritance. Thirty-five genes of EE have been identified and the search is still continuing. The marked genetic heterogeneity of early EE, including 16 with autosomal-dominant-, 13 with autosomal-recessive-, 4 with X-linked recessive- and 2 with X-linked autosomal inheritance, was shown. The article describes differentiated approaches to the treatment of certain EE syndromes. Recent publications record the effectiveness of targeted therapy for certain forms of monogenic early EE (stiripentol in SCN1A mutations, diphenine in SCN8A mutations, levetiracetam in STXBP1 mutations). These results indicate the necessity for accurate diagnosis of genetic variants in early infantile EE for preventive actions in burdened families and for increasing the effectiveness of treatment.
More Related Videos
07:01Electrophoretic Delivery of γ-aminobutyric Acid GABA into Epileptic Focus Prevents Seizures in Mice
Published on: May 16, 2019
08:22A Novel Strategy Combining Array-CGH, Whole-exome Sequencing and In Utero Electroporation in Rodents to Identify Causative Genes for Brain Malformations
Published on: December 1, 2017
Related Concept Videos
Epilepsy and Seizures: Overview
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Seizures: Classification
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Electroconvulsive Therapy
Antiepileptic Drugs: Glutamate Antagonists
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
